Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report

@inproceedings{Patti2015ClinicalAR,
  title={Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report},
  author={Francesco Patti and Carmela Leone and Mario Zappia},
  booktitle={BMC Neurology},
  year={2015}
}
BackgroundThe evidence on the use of the oral dimethyl-fumarate after the discontinuation of treatment with natalizumab in people with Multiple Sclerosis is still little. Natalizumab discontinuation may induce the recurrence or rebound of the clinical and neuroradiological disease activity. Currently no therapeutic approach has been established to abolish disease reactivation and rebound after natalizumab interruption.Case PresentationWe describe a case of a 21-year-old woman affected from a… CONTINUE READING
2
Twitter Mentions

Figures and Topics from this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Comparative analysis of oral disease-modifying therapies after natalizumab withdrawal in patients with multiple sclerosis

N Hadhoum, O Outteryck, +3 authors A Kwiatkowski
  • ECTRIMS
  • 2015
VIEW 2 EXCERPTS

Efficacy of oral Multiple Sclerosis therapies in patients switching from natalizumab

N Vu, H Moses, S Siriam, S. Pawate
  • Neurology
  • 2015
VIEW 2 EXCERPTS

Efficacy of oral Multiple Sclerosis therapies in patients switching from natalizumab ( P 3 . 290 )

N Vu, H Moses, S Siriam, S Pawate
  • Neurology
  • 2015

a post-marketing study

G Borriello, L Prosperini, +3 authors natalizumab Pozzilli C. Pulse monthly steroids during an elect of
  • Eur J Neurol. 2012;19:783–7. • We accept pre-submission inquiries • Our selector tool helps you to find the most relevant journal • We provide round the clock customer support • Convenient online submission • Thorough peer review • Inclusion in PubMed and all major indexing services • Maximum visib
  • 2015
VIEW 1 EXCERPT